tbuckley/cabot-search huggingface dataset:
A weighted risk index had moderate ability to predict VTE requiring treatment after outpatient surgery
Authors: Juan I. Arcelus
Journal: Annals of Internal Medicine (2013)

Clinical Prediction Guide19 February 2013A weighted risk index had moderate ability to predict VTE requiring treatment after outpatient surgeryJuan I. Arcelus, MD, PhDJuan I. Arcelus, MD, PhDUniversity of Granada Medical School, Granada, Spain (J.I.A.)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-158-4-201302190-02012 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Source CitationPannucci CJ, Shanks A, Moote MJ, et al. Identifying patients at high risk for venous thromboembolism requiring treatment after outpatient surgery. Ann Surg. 2012;255:1093-9. https://pubmed.ncbi.nlm.nih.gov/22584630Clinical Impact RatingsHematology: Author, Article, and Disclosure InformationAffiliations: University of Granada Medical School, Granada, Spain (J.I.A.)This article was published at Annals.org on 5 February 2013. Nextarticle Advertisement FiguresReferencesRelatedDetails Metrics 19 February 2013Volume 158, Issue 4Page: JC12KeywordsArthroscopyDatabasesMedical risk factorsOutpatientsProphylaxisQuality improvementSurgeonsSurgeryVeinsVenous thromboembolism ePublished: 19 February 2013 Issue Published: 19 February 2013 CopyrightCopyright © 2013 by American College of Physicians. All Rights Reserved.PDF DownloadLoading ...
MicroRNAs Impair MET-Mediated Invasive Growth
Authors: Cristina Migliore, Annalisa Petrelli, Elena Ghiso, Simona Corso, Lorena Capparuccia, Adriana Eramo, Paolo M. Comoglio, Silvia Giordano
Journal: Cancer Research (2008)

Abstract MicroRNAs (miRNA) are a recently identified class of noncoding, endogenous, small RNAs that regulate gene expression, mainly at the translational level. These molecules play critical roles in several biological processes, such as cell proliferation and differentiation, development, and aging. It is also known that miRNAs play a role in human cancers where they can act either as oncogenes, down-regulating tumor suppressor genes, or as onco-suppressors, targeting molecules critically involved in promotion of tumor growth. One of such molecules is the tyrosine kinase receptor for hepatocyte growth factor, encoded by the MET oncogene. The MET receptor promotes a complex biological program named “invasive growth” that results from stimulation of cell motility, invasion, and protection from apoptosis. This oncogene is deregulated in many human tumors, where its most frequent alteration is overexpression. In this work, we have identified three miRNAs (miR-34b, miR-34c, and miR-199a*) that negatively regulate MET expression. Inhibition of these endogenous miRNAs, by use of antagomiRs, resulted in increased expression of MET protein, whereas their exogenous expression in cancer cells blocked MET-induced signal transduction and the execution of the invasive growth program, both in cells expressing normal levels of MET and in cancer cells overexpressing a constitutively active MET. Moreover, we show that these same miRNAs play a role in regulating the MET-induced migratory ability of melanoma-derived primary cells. In conclusion, we have identified miRNAs that behave as oncosuppressors by negatively targeting MET and might thus provide an additional option to inhibit this oncogene in tumors displaying its deregulation. [Cancer Res 2008;68(24):10128–36]
Payment Restrictions for Prescription Drugs under Medicaid
Authors: Stephen Bertram Soumerai, Jerry Lewis Avorn, Dennis Ross-Degnan, Steven L. Gortmaker
Journal: New England Journal of Medicine (1987)

In an attempt to contain costs, 27 Medicaid programs have implemented patient-level payment limits for medications, but the effects of these restrictions on quality of care, costs, and health status remain largely unknown. We measured the effect of one state's limit of three paid prescriptions per month and its replacement a year later by a $1 copayment. Using data on 48 months of claims in the study state (New Hampshire) and a comparison state (New Jersey), we employed time-series analysis to evaluate patient-level changes in the number of prescriptions filled for 16 drugs that varied in their clinical importance and cost. Among 10,734 continuously enrolled patients, the limit of three paid prescriptions per month caused a sudden, sustained drop of 30 percent in the number of prescriptions filled (from 1.10 to 0.77 prescriptions per patient per month); no change was observed in the comparison state. The 860 recipients of multiple drugs, who were predominantly female and elderly or disabled, were most severely affected; the number of prescriptions per month dropped from 5.2 to 2.8 (46 percent). The decrease was greatest for "ineffective drugs" (58 percent), but large drops were also observed for "essential" medications, such as insulin (28 percent), thiazides (28 percent), and furosemide (30 percent). Reductions in Medicaid prescriptions were minimally offset by increases in the size of the prescription or in out-of-pocket payments. When a $1 copayment replaced the three-prescription cap, prescriptions for most medications increased to just below precap levels. Medicaid's savings on drug costs resulting from both policies were comparable ($0.4 to $0.8 million annually), but the copayment policy had less effect on patients receiving multiple drugs. Because the clinical consequences of such policies cannot be assessed from prescription data alone, further study is needed to determine the effects of cost-containment strategies on health status and the use of other services among poor populations.
Continuous lumbar epidural analgesia for labour and delivery.
Authors: J S Crawford
Journal: BMJ (1979)

Plasma hormonal responses to insulin hypoglycaemia and to oral and intravenous glucose were investigated in chagasic patients with severe bowel disease and compared with controls matched for age, sex, weight, and race. After intravenous insulin, plasma concentrations of pancreatic glucagon and pancreatic polypeptide (PP) were reduced in the patients with Chagas9s disease. These subjects also showed a subnormal rise in plasma insulin after oral glucose. Other hormone responses did not differ significantly from those in the normal controls. These results are compatible with partial denervation of the pancreatic alpha, beta, and PP cells in patients with chronic gastrointestinal Chagas9s disease.
The Painful Shoulder
Authors: P. D. Wilson
Journal: BMJ (1939)

Shoulder pain may be due to a host of causes, and in order to transfer the discussion of this subject from an abstract to a specific basis I SLubmit the following analysis of diagnoses from 168 personally studied cases seen during the last five years.This list is presented with due apology for its shortcomings and with the full knowledge that it represents nothing more than the experience of an individual surgeon.Its only merit lies in the fact that it includes all patients seen during this period who com- plained primarily of the shoulder, and that it gives an indication of the variety of conditions that must be included in the differential diagnosis.TABLE 1.-Showing Analysis of Diagnioses of 168 Personally
INTUBATION IN DIPHTHERIA.Read before The Mitchell, Ind., District Medical Society, Dec., 17, 1891.
Authors: P. RICHARD TAYLOR
Journal: JAMA (1892)

I will make a strictly clinical report of four cases of intubation, selected from a number during the recent endemic of diphtheria in Louisville, two of which were fatal, and two successful. <i>Case i</i>.—Oct. 29th; I was called by Dr. Ernest Yeager to intubate the larynx of Robt. W., æt. 7 years and 5 months. On examination I found diphtheritic patches on the tonsils and in the pharynx. In the larynx the mucous membrane was swollen and tumefied, but there was no false membrane. Respiration, 36 per minute; pulse 150 and thready; temperature 102½. He was in a semi-comatose condition and very much cyanosed. The intercostal spaces were depressed and did not rise with inspiration. The dyspnœa was distressing. A tube the size required for an eight year old child, was introduced into the trachea, which relieved the dyspnœa immediately. At the end of an hour, respiration was 22; pulse,
Re-treating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: Really safe and effective?
Authors: Gin-Ho Lo
Journal: Hepatology (2009)

I read with interest the article by Bacon et al.1 dealing with the retreatment of chronic hepatitis C with daily interferon alfacon-1 (CIFN)/ribavirin (RBV) for patients who were nonresponders to pegylated interferon (PEG-IFN)/RBV. As expected, the treatment of these patients who were nonresponders to PEG-IFN/RBV has been very difficult. Several studies have evaluated the efficacy of retreatment with PEG-IFN/RBV and some successes have been achieved. Overall response rates ranging from 18%–41% have been reported.2-4 Generally, previous nonresponders (defined as detectable hepatitis C virus [HCV] RNA at the end of treatment) had a lower sustained virological response (SVR), whereas previous relapsers (defined as undetectable HCV RNA at the end of therapy) had a higher SVR.4 Because this trial by Bacon et al. enrolled patients who had a < 2 log10 decrease in HCV RNA between weeks 12 and 24 or detectable HCV RNA at weeks 24 or 48, the rates of previous nonresponders and relapsers were not disclosed. This study showed that SVR rates were 6.9% in the 9-μg group and 10.7% in the 15-μg group. Only a subgroup of patients (with fibrosis scores of F0–F3) who received 15 μg could achieve SVR in 31.6% of individuals if a > 2 log10 decrease in HCV RNA was attained with previous PEG-IFN/RBV therapy. The proportion of patients who could not tolerate adverse events of CIFN/RBV and who required discontinuation was up to 17.7%. The authors concluded that retreatment of nonresponders to PEG-IFN/RBV with CIFN/RBV is safe and efficacious. Undeniably, the SVR would be 0% in patients who experienced PEG-IFN/RBV treatment failure, under "watchful waiting". However, if the SVR ranging from 6%–10% was interpreted as efficacious, this may be misleading for readers. Overall, the alternative strategies for improving SVR in PEG-IFN/RBV nonresponders have not met with success just like that stated by the authors. Based on the current data, retreatment of chronic hepatitis C with daily CIFN/RBV for patients who were nonresponders to PEG-IFN/RBV should be interpreted as ineffective except for a subgroup of patients. Gin-Ho Lo M.D.*, * Department of Medical Education; Digestive Center, E-Da Hospital-I_SHOU University, Kaohsiung, Taiwan.
Clinical Case Reporting in Evidence-based Medicine
Authors: Edward J. Huth
Journal: Annals of Internal Medicine (2001)

Medical Writings: Book Notes20 February 2001Clinical Case Reporting in Evidence-based MedicineEdward J. Huth, MDEdward J. Huth, MDBryn Mawr, Pennsylvania. (Huth)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-134-4-200102200-00034 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail Jenicek M. 154 pages. Oxford, UK: Butterworth–Heinemann; 1999. $16.99. ISBN 075064592X. Order phone 800-366-2665.Field of medicine:All clinical fields.Format:Softcover book.Audience:Clinicians who present cases in conferences or prepare case reports and case-series reviews for publication in journals.Purpose:To show why case reports with appropriate content are useful for teaching medical thinking and suggesting hypotheses that merit further study.Content:The opening two chapters discuss historic and present uses of case reports and serve as a prelude of rationale for the author's close attention in the third chapter to the work of organizing materials for case reports and to the kinds ... Author, Article, and Disclosure InformationAffiliations: Bryn Mawr, Pennsylvania. (Huth) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 20 February 2001Volume 134, Issue 4Page: 348KeywordsCase seriesEvidence based medicineForecastingSoftware toolsSystematic reviews ePublished: 20 February 2001 Issue Published: 20 February 2001 Copyright & PermissionsCopyright © 2001 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Psychological impact of alopecia
Authors: Antonio E Nardi
Journal: BMJ (2005)

Endovascular repair is not worse than open repair of abdominal aortic aneurysmsEditor-The title and interpretation of the EVAR trial results in the POEM are misleading and incorrect. 1Mortality figures were quoted both as aneurysm related and all cause deaths.The 30 day mortality was 1.7% in the EVAR group, which is significantly lower than 4.7% in the open repair group.Surprisingly, the POEM somehow interpreted 30 day mortality to be less than 1% for both groups, which is clearly an error.The confidence intervals (odds ratio 0.35, 95% confidence interval 0.16 to 0.77, P = 0.009) make type I error unlikely.If preintervention deaths are added to the figures 30 day mortality was calculated at 3.5% for endovascular repair and 7.1% for open surgery. 2 The advantage of endovascular repair is sustained at four years, with 4% aneurysm related deaths in the EVAR group compared with 7% in the open repair group.This confers a 3% absolute reduction in aneurysm related mortality.The all cause mortality rate was comparable in both groups at four years.Endovascular repair offers a 30 day lower risk treatment compared with open surgery in patients who are medically fit with an abdominal aortic aneurysm.Compared with open repair, endovascular repair offers no advantage with respect to all cause mortality and health related quality of life; and is more expensive; however, it confers a 3% improved aneurysm related survival which persists at four years.The POEM's message that endovascular repair is worse than open repair is inaccurate and not evidence based.
Up-regulation of <i>miR-200</i> and <i>let-7</i> by Natural Agents Leads to the Reversal of Epithelial-to-Mesenchymal Transition in Gemcitabine-Resistant Pancreatic Cancer Cells
Authors: Yiwei Li, Timothy G. VandenBoom, Dejuan Kong, Zhiwei Wang, Shadan Ali, Philip A. Philip, Fazlul H. Sarkar
Journal: Cancer Research (2009)

Abstract Pancreatic cancer is the fourth most common cause of cancer death in the United States, and the aggressiveness of pancreatic cancer is in part due to its intrinsic and extrinsic drug resistance characteristics, which are also associated with the acquisition of epithelial-to-mesenchymal transition (EMT). Emerging evidence also suggests that the processes of EMT are regulated by the expression status of many microRNAs (miRNA), which are believed to function as key regulators of various biological and pathologic processes during tumor development and progression. In the present study, we compared the expression of miRNAs between gemcitabine-sensitive and gemcitabine-resistant pancreatic cancer cells and investigated whether the treatment of cells with “natural agents” [3,3′-diindolylmethane (DIM) or isoflavone] could affect the expression of miRNAs. We found that the expression of miR-200b, miR-200c, let-7b, let-7c, let-7d, and let-7e was significantly down-regulated in gemcitabine-resistant cells, which showed EMT characteristics such as elongated fibroblastoid morphology, lower expression of epithelial marker E-cadherin, and higher expression of mesenchymal markers such as vimentin and ZEB1. Moreover, we found that reexpression of miR-200 by transfection studies or treatment of gemcitabine-resistant cells with either DIM or isoflavone resulted in the down-regulation of ZEB1, slug, and vimentin, which was consistent with morphologic reversal of EMT phenotype leading to epithelial morphology. These results provide experimental evidence, for the first time, that DIM and isoflavone could function as miRNA regulators leading to the reversal of EMT phenotype, which is likely to be important for designing novel therapies for pancreatic cancer. [Cancer Res 2009;69(16):6704–12]
506 Antiviral therapy (AT) decreases hepatic venous pressure gradient (HVPG) in patients with chronic hepatitis C (CHC) and fibrotic stage (FS) 3 or 4
Authors: D. Rincon, R. Banares, M. Salcedo, S. Alonso, C. Ripoll, M.V. Catalina, E. Alvarez, G. Clemente
Journal: Journal of Hepatology (2004)
Destructive Polyarthritis Due to a Photochromogenic Mycobacterium
Authors: James R. Klinenberg, Philip M. Grimley, J. E. Seegmiller
Journal: New England Journal of Medicine (1965)

RECENTLY there has been increasing clinical awareness of a group of micro-organisms, variously named the "anonymous," "atypical," "saprophytic" or "unclassified" mycobacteria, which are apparently related to Mycobacterium tuberculosis but differ in certain cultural, metabolic and colonial features.1 These organisms have been reported as the cause of human pulmonary disease2 and cervical adenitis,3 but there have been only a few reports of bone or joint involvement.4 5 6 7 8 The present case of destructive polyarthritis due to an anonymous mycobacterium not only posed an interesting problem in differential diagnosis but is the first known to have responded favorably to antituberculous therapy.Case ReportJ.P., . . .
Abstract 640: Human MutS homologue 4 (hMSH4) interacts with eIF3f and inhibits NHEJ-mediated DNA repair.
Authors: Xiling Wu, Yen-Lin Chu, Chengtao Her
Journal: Cancer Research (2013)

Abstract DNA mismatch repair (MMR) proteins participate in diverse cellular functions including DNA damage response and repair. As a member of the MMR family, hMSH4 plays an important role in meiotic recombination, likely through the formation of hMSH4-hMSH5 heterocomplex that interacts with homologous recombination DNA intermediate structures. It is known that hMSH4 is expressed in an array of somatic cells; however, its involvement in mitotic processes is poorly defined. We have identified a new hMSH4 interacting partner eIF3f, a protein that functions not only in translation but also in the regulation of apoptosis and tumorigenesis. Our studies have demonstrated that hMSH4-eIF3f interaction is mediated through the N-terminal regions of both proteins. The interaction with eIF3f stabilizes hMSH4 protein, which in turn sustains DNA double strand break (DSB)-induced γ-H2AX foci and compromises cell survival in response to ionizing radiation (IR). These effects could be attributed to the inhibition of NHEJ activity by hMSH4. Furthermore, hMSH4 reduces IR-induced AKT activation, thereby facilitating eIF3f-mediated bypass of S phase arrest, and ultimately promoting G2/M arrest in response to IR treatment. In short, this study revealed a potential role of hMSH4 in the maintenance of genomic stability through suppressing error-prone DSB repair. Citation Format: Xiling Wu, Yen-Lin Chu, Chengtao Her. Human MutS homologue 4 (hMSH4) interacts with eIF3f and inhibits NHEJ-mediated DNA repair. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 640. doi:10.1158/1538-7445.AM2013-640
714-2 Diffuse Cardiac Sympathetic Dysfunction Follows Implantable Defibrillator Shocks Delivered Through Epicardial Patch Electrodes
Authors: Lawrence B. Rigden, Raul D. Mitrani, David P. Rardon, Lawrence S. Klein, Yousuf Mahomed, Henry N. Wellman, William M. Miles, Douglas P. Zipes
Journal: Journal of the American College of Cardiology (1995)
5-Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis
Authors: HERBERT HONIGSMANN, ERNA JASCHKE, FRITZ GSCHNAIT, WILHELM BRENNER, PETER FRITSCH, KLAUS WOLFF
Journal: British Journal of Dermatology (1979)

Journal Article 5‐Methoxypsoralen (Bergapten) in photochemotherapy of psoriasis Get access HERBERT HÖNIGSMANN, HERBERT HÖNIGSMANN Department of Dermatology, University of Innsbruck, Austria Dr H. Hönigsmann, Department of Dermatology, University of Innsbruck, Anichstrasse 35, A‐6020 Innsbruck, Austria. Search for other works by this author on: Oxford Academic Google Scholar ERNA JASCHKE, ERNA JASCHKE Department of Dermatology, University of Innsbruck, Austria Search for other works by this author on: Oxford Academic Google Scholar FRITZ GSCHNAIT, FRITZ GSCHNAIT Department of Dermatology (I), University of Vienna, Austria Search for other works by this author on: Oxford Academic Google Scholar WILHELM BRENNER, WILHELM BRENNER Department of Dermatology (I), University of Vienna, Austria Search for other works by this author on: Oxford Academic Google Scholar PETER FRITSCH, PETER FRITSCH Department of Dermatology, University of Innsbruck, Austria Search for other works by this author on: Oxford Academic Google Scholar KLAUS WOLFF KLAUS WOLFF Department of Dermatology, University of Innsbruck, Austria Search for other works by this author on: Oxford Academic Google Scholar British Journal of Dermatology, Volume 101, Issue 4, 1 October 1979, Pages 369–378, https://doi.org/10.1111/j.1365-2133.1979.tb00014.x Published: 01 October 1979
Hypercalcemia in an Anephric Patient with Sarcoidosis: Evidence for Extrarenal Generation of 1,25-Dihydroxyvitamin D
Authors: Galen L. Barbour, Jack W. Coburn, Eduardo Slatopolsky, Anthony W. Norman, Ronald L. Horst
Journal: New England Journal of Medicine (1981)

HYPERCALCEMIA can occur in up to 10 per cent of patients with sarcoidosis.1 , 2 During the active phase of the disease, increased absorption of calcium from the intestine leads to hypercalciuria and occasionally hypercalcemia. The increased absorption of calcium is presumed to be secondary to increased sensitivity to vitamin D,3 and it may be decreased or abolished by the development of concomitant renal failure.4 Recent reports have identified elevated circulating levels of 1,25-dihydroxyvitamin D (1,25-[OH]2D) in hypercalcemic patients with sarcoidosis, and it has been suggested that such patients produce increased amounts of 1,25-(OH)2D3 from vitamin D. . . .
Psycho-Oncology: Journal of the Psychological, Social and Behavioral Dimensions of Cancer
Authors: Marjorie A. Sirridge
Journal: JAMA (1994)

<i>Psycho-Oncology</i>is a quarterly, peer-reviewed publication, which, according to its statement of purpose, "addresses the two major psychological dimensions of cancer: the psychological responses of patients to cancer at all stages of the disease and that of their families and caretakers and the psychological, behavioral and social factors that may influence the disease process." The editorial board is relatively large and includes persons from a wide variety of disciplines, countries, and institutions. Of the 32 members, only 10 represent institutions in the United States. Combining psychological, social, behavioral, and ethical aspects of cancer is a relatively new concept, and few centers have significant concentrations of persons who have expertise in these subject areas. This broad representation is a real asset in setting the tone for the journal, which is published on behalf of the British Psycho-Oncology Group and the American Society of Psychiatric Oncology and is recommended by six similar